ArticleDiscover oncology2024
DYNLL1 ubiquitinated and degraded by E3 ligase PRKN regulates cell cycle arrest and apoptosis in lung adenocarcinoma cells.
Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ubiquitin-Conjugating Enzyme Positively Regulates Salicylic Acid and Jasmonic Acid Biosynthesis to Confer Broad-Spectrum Antiviral Resistance inPlants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was intended to investigate the role of DYNLL1 in lung adenocarcinoma (LUAD) and reveal the relevant molecular mechanism. To this end, we manipulated the expression of DYNLL1 and PRKN with shRNA and/or overexpression to assess their effects on A549 cell phenotypes including cell proliferation, cycle arrest and apoptosis using CCK-8 assay, EdU staining, colony formation assay, flow cytometry, TUNEL and western blot. DYNLL1 is a carcinogenic factor in LUAD since it is highly expressed and DYNLL1 upregulation is associated with the low overall survival rate of LUAD patients. Silencing DYNLL1 inhibited the proliferation of LUAD cells while accelerating cell cycle arrest and apoptosis. The regulatory effects of silencing DYNLL1 were counteracted by PRKN deficiency, indicating a functional connection between DYNLL1 and PRKN, which could be attributed to the ubiquitination of DYNLL1 by PRKN. This study could help identify the role of DYNLL1 in LUAD pathogenies and develop reliable therapeutic targets for LUAD improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.